Polyclonal Antibody to Receptor Interacting Serine Threonine Kinase 3 (RIPK3)
Code | Size | Price |
---|
PAE639Ra01-20ul | 20ul | £92.00 |
Quantity:
PAE639Ra01-100ul | 100ul | £173.00 |
Quantity:
PAE639Ra01-200ul | 200ul | £234.00 |
Quantity:
PAE639Ra01-1ml | 1ml | £539.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
RIP3; RIP-like protein kinase 3; Receptor-interacting protein 3
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Receptor Interacting Serine Threonine Kinase 3
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Receptor Interacting Serine Threonine Kinase 3 (RIPK3) | RPE639Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||